Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.85 |
| ▸ | GAK | O14976 | 4/20 | 0.85 |
| ▸ | ILK | Q13418 | 3/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.85 |
| ▸ | BUB1 | O43683 | 2/20 | 0.85 |
| ▸ | STK10 | O94804 | 2/20 | 0.85 |
| ▸ | ABL1 | P00519 | 2/20 | 0.85 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | SRC | P12931 | 2/20 | 0.85 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.85 |
| ▸ | FECH | P22830 | 2/20 | 0.85 |
| ▸ | KDR | P35968 | 2/20 | 0.85 |
| ▸ | FLT3 | P36888 | 2/20 | 0.85 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.85 |
| ▸ | PLK4 | O00444 | 1/20 | 0.85 |
| ▸ | CIT | O14578 | 1/20 | 0.85 |
| ▸ | AURKA | O14965 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL30362833 | 0.92 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL3667407 | 0.92 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL29351329 | 0.92 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL8413 | 0.92 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL16767632 | 0.91 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL21176918 | 0.91 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL29460839 | 0.91 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL18563 | 0.91 | EGFR (1.00) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL417841 | 0.91 | EGFR (0.98) | EGFRERBB2GAKILKRIPK2 | |
| Erlotinib SCHEMBL1959332 | 0.91 | EGFR (0.98) | EGFRERBB2GAKILKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169134-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | RENOTARGET THERAPEUTICS INC. | 2019-06-06 | — | — | US | disclosed |
| US-10202357-B2 | Class of quinolone heterocyclic aromatic molecules for cancer treatment | RenoTarget Therapeutics, Inc. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018089269-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | RENOTARGET THERAPEUTICS INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127383-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | RENOTARGET THERAPEUTICS INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127383-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | RENOTARGET THERAPEUTICS INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202357-B2 | Class of quinolone heterocyclic aromatic molecules for cancer treatment | EGFR, ABL1, NRAS | EGFR 1/4885ERBB2 4/4885GAK 540/4885 |
| US-20180127383-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | EGFR, NRAS, ABL1 | EGFR 1/4885ERBB2 5/4885GAK 566/4885 |
| US-20190169134-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | EGFR, NRAS, HRAS | EGFR 1/4885ERBB2 8/4885GAK 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.